MedTrace Logo

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 790

Last updated 2024-12-09

No results posted yet for this study

Summary

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

Conditions

Interventions

DRUG

VYD222 (pemivibart)

Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.

DRUG

Normal saline

Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.

Sponsors & Collaborators

  • Invivyd, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2024-11-19
Completion
2024-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06039449 on ClinicalTrials.gov